Our results demonstrate for the first time that luteolin can act as inhibitor of SphK2, the predominant SphK isoform in the used CC cell line, as well as in several colon cancer cell lines [45], but exerts only a modest, if any, effect on SphK1 activity. Here, SPHK1 is linked to colonic neoplasm.